Anti-S52A3/ SLC52A3/ BVVLS monoclonal antibody

Anti-S52A3/ SLC52A3/ BVVLS antibody for FACS & in-vivo assay

Target products collectionGo to SLC52A3/SLC52A3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1647-Ab-1/ GM-Tg-hg-MP1647-Ab-2Anti-Human SLC52A3 monoclonal antibodyHuman
GM-Tg-rg-MP1647-Ab-1/ GM-Tg-rg-MP1647-Ab-2Anti-Rat SLC52A3 monoclonal antibodyRat
GM-Tg-mg-MP1647-Ab-1/ GM-Tg-mg-MP1647-Ab-2Anti-Mouse SLC52A3 monoclonal antibodyMouse
GM-Tg-cynog-MP1647-Ab-1/ GM-Tg-cynog-MP1647-Ab-2Anti-Cynomolgus/ Rhesus macaque SLC52A3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1647-Ab-1/ GM-Tg-felg-MP1647-Ab-2Anti-Feline SLC52A3 monoclonal antibodyFeline
GM-Tg-cang-MP1647-Ab-1/ GM-Tg-cang-MP1647-Ab-2Anti-Canine SLC52A3 monoclonal antibodyCanine
GM-Tg-bovg-MP1647-Ab-1/ GM-Tg-bovg-MP1647-Ab-2Anti-Bovine SLC52A3 monoclonal antibodyBovine
GM-Tg-equg-MP1647-Ab-1/ GM-Tg-equg-MP1647-Ab-2Anti-Equine SLC52A3 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1647-Ab-1/ GM-Tg-hg-MP1647-Ab-2; GM-Tg-rg-MP1647-Ab-1/ GM-Tg-rg-MP1647-Ab-2;
GM-Tg-mg-MP1647-Ab-1/ GM-Tg-mg-MP1647-Ab-2; GM-Tg-cynog-MP1647-Ab-1/ GM-Tg-cynog-MP1647-Ab-2;
GM-Tg-felg-MP1647-Ab-1/ GM-Tg-felg-MP1647-Ab-2; GM-Tg-cang-MP1647-Ab-1/ GM-Tg-cang-MP1647-Ab-2;
GM-Tg-bovg-MP1647-Ab-1/ GM-Tg-bovg-MP1647-Ab-2; GM-Tg-equg-MP1647-Ab-1/ GM-Tg-equg-MP1647-Ab-2
Products NameAnti-SLC52A3 monoclonal antibody
Formatmab
Target NameSLC52A3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SLC52A3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species S52A3/ SLC52A3/ BVVLS VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1647
    Target NameSLC52A3
    Gene ID113278,69698,311536,715057,100856604,101091010,507459,100067845
    Gene Symbol and Synonyms2310046K01Rik,bA371L19.1,BVVLS,BVVLS1,C13H20orf54,C20orf54,C24H20orf54,hRFT2,RFT2,RFVT3,RGD1304644,rRFT2,SLC52A3
    Uniprot AccessionQ9NQ40,Q4FZU9,Q5E9R1
    Uniprot Entry NameS52A3_HUMAN,S52A3_RAT,S52A3_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000101276
    Target ClassificationN/A

    The target: SLC52A3, gene name: SLC52A3, also named as BVVLS, BVVLS1, C20orf54, RFT2, RFVT3, bA371L19.1, hRFT2. This gene encodes a riboflavin transporter protein that is strongly expressed in the intestine and likely plays a role in intestinal absorption of riboflavin. The protein is predicted to have eleven transmembrane domains and a cell surface localization signal in the C-terminus. Mutations at this locus have been associated with Brown-Vialetto-Van Laere syndrome and Fazio-Londe disease. [provided by RefSeq, Mar 2012].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.